Hepatocyte growth factor in dampening liver immune-mediated pathology in acute viral hepatitis without compromising antiviral activity
Renan Aguilar-Valenzuela
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
Search for more papers by this authorEric D. Carlsen
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
Search for more papers by this authorYuejin Liang
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
Search for more papers by this authorLynn Soong
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
Department of Pathology, The University of Texas Medical Branch, Galveston, Texas, USA
Search for more papers by this authorCorresponding Author
Jiaren Sun
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
Correspondence
Dr Jiaren Sun, Department of Microbiology and Immunology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-1070, USA. Email: [email protected]
Search for more papers by this authorRenan Aguilar-Valenzuela
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
Search for more papers by this authorEric D. Carlsen
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
Search for more papers by this authorYuejin Liang
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
Search for more papers by this authorLynn Soong
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
Department of Pathology, The University of Texas Medical Branch, Galveston, Texas, USA
Search for more papers by this authorCorresponding Author
Jiaren Sun
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
Correspondence
Dr Jiaren Sun, Department of Microbiology and Immunology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-1070, USA. Email: [email protected]
Search for more papers by this authorAbstract
Background and Aim
Hepatocyte growth factor (HGF) is a pleiotropic cytokine related with cell proliferation and survival; however, its role in viral hepatitis is not elucidated. In this study, we studied HGF immune role in viral hepatitis.
Methods
Mice received hydrodynamically delivered HGF plasmid or control plasmid and then infected with adenovirus, and parameters of immune-mediated liver damage were evaluated. We studied dendritic cell (DC) activation in the presence of HGF. T cells collected from infected mice were restimulated with virally infected DC to measure cytokine production in vitro.
Results
HGF ameliorated the liver inflammation during viral hepatitis as alanine transferase, intrahepatic lymphocytes, and splenocyte counts were diminished by HGF. Lower histological scores of liver pathology were observed in the HGF group. DC from the HGF group expressed reduced CD40. The hepatic expression and serum concentration of IL-12p40 were diminished in HGF-transfected mice. In vitro experiments with DC confirmed that HGF diminished CD40 expression and IL-12p40 production. The expression and serum levels of IFN-γ, IL-6 and CXCL9 were significantly decreased in the HGF group. HGF overexpression diminished the expression and concentration of IL-10 and TGF-β. The frequency of PD-1+Tim-3+ in CD8 T cells was decreased by HGF overexpression. Moreover, T cells in the HGF group at day 14 secreted more IFN-γ and TNF-α than those in the control group when restimulated with virally infected DC.
Conclusion
HGF modulated DC activation and T cell priming, thereby limiting the immune-mediated damage in the liver. However, viral clearance was not compromised by HGF.
References
- 1 Botterel F, Farrugia C, Ichai P, Costa JM, Saliba F, Bretagne S. Real-time PCR on the first galactomannan-positive serum sample for diagnosing invasive aspergillosis in liver transplant recipients. Transpl. Infect. Dis. 2008; 10: 333–338.
- 2 Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008; 14 (Suppl. 2): S67–79.
- 3 Barnes E, Folgori A, Capone S et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 2012; 4: 115ra1.
- 4 Raper SE, Chirmule N, Lee FS et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003; 80: 148–158.
- 5 Ajuebor MN, Chen Q, Strieter RM, Adegboyega PA, Aw TY. V(alpha)14iNKT cells promote liver pathology during adenovirus infection by inducing CCL5 production: implications for gene therapy. J. Virol. 2010; 84: 8520–8529.
- 6 Benkhoucha M, Santiago-Raber ML, Schneiter G et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc. Natl Acad. Sci. U.S.A. 2010; 107: 6424–6429.
- 7 Burcelin R, Garidou L, Pomie C. Immuno-microbiota cross and talk: the new paradigm of metabolic diseases. Semin. Immunol. 2012; 24: 67–74.
- 8 Makino H, Aoki M, Hashiya N et al. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler. Thromb. Vasc. Biol. 2012; 32: 2503–2509.
- 9 Morimoto K, Amano H, Sonoda F et al. Alveolar macrophages that phagocytose apoptotic neutrophils produce hepatocyte growth factor during bacterial pneumonia in mice. Am. J. Respir. Cell Mol. Biol. 2001; 24: 608–615.
- 10 Grenier A, Chollet-Martin S, Crestani B et al. Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils. Blood 2002; 99: 2997–3004.
- 11 Giannopoulou M, Dai C, Tan X, Wen X, Michalopoulos GK, Liu Y. Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling. Am. J. Pathol. 2008; 173: 30–41.
- 12 Ueki T, Kaneda Y, Tsutsui H et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. 1999; 5: 226–230.
- 13 Baek JH, Birchmeier C, Zenke M, Hieronymus T. The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J. Immunol. 2012; 189: 1699–1707.
- 14 Imado T, Iwasaki T, Kataoka Y et al. Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation. Blood 2004; 104: 1542–1549.
- 15 Kosai K, Matsumoto K, Funakoshi H, Nakamura T. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology 1999; 30: 151–159.
- 16 Okunishi K, Dohi M, Fujio K et al. Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice. J. Immunol. 2007; 179: 5504–5513.
- 17 Giebeler A, Boekschoten MV, Klein C et al. c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Gastroenterology 2009; 137: 297–308; e1–4.
- 18 Okunishi K, Dohi M, Nakagome K et al. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J. Immunol. 2005; 175: 4745–4753.
- 19 Yang J, Chen S, Huang L, Michalopoulos GK, Liu Y. Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth. Hepatology 2001; 33: 848–859.
- 20 Coudriet GM, He J, Trucco M, Mars WM, Piganelli JD. Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. PLoS ONE 2010; 5: e15384.
- 21 Gordin M, Tesio M, Cohen S et al. c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J. Immunol. 2010; 185: 2020–2031.
- 22 Xia JL, Dai C, Michalopoulos GK, Liu Y. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am. J. Pathol. 2006; 168: 1500–1512.
- 23 Mizuno S, Matsumoto K, Kurosawa T, Mizuno-Horikawa Y, Nakamura T. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice. Kidney Int. 2000; 57: 937–948.
- 24 Okayama K, Azuma J, Dosaka N et al. Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension 2012; 59: 958–965.
- 25 Lee JJ, Liu D, Lee JS et al. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J. Natl Cancer Inst. 2001; 93: 1081–1088.
- 26 Schmitz V, Dombrowski F, Prieto J et al. Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. Hepatology 2006; 44: 430–439.
- 27 Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433–442.
- 28 Maier H, Isogawa M, Freeman GJ, Chisari FV. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J. Immunol. 2007; 178: 2714–2720.
- 29 Lang KS, Georgiev P, Recher M et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 2006; 116: 2456–2463.
- 30 Rosenblum JM, Shimoda N, Schenk AD et al. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors. J. Immunol. 2010; 184: 3450–3460.
- 31 Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007; 15: 143–146.
- 32 Kerdiles YM, Beisner DR, Tinoco R et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 2009; 10: 176–184.
- 33 Bu X, Zhou Y, Zhang H et al. Systemic administration of naked plasmid encoding HGF attenuates puromycin aminonucleoside-induced damage of murine glomerular podocytes. Am. J. Physiol. Renal Physiol. 2011; 301: F784–792.
- 34 Oketani M, Ido A, Nakayama N et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol. Res. 2013; 43: 97–105.
- 35 Marin-Serrano E, Jaquotot-Herranz M, Casanova-Martinez L, Tur-Gonzalez R, Segura-Cabral JM. Ectopic sebaceous glands in the esophagus. Rev. Esp. Enferm. Dig. 2010; 102: 141–142.
- 36 Funakoshi H, Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clin. Chim. Acta 2003; 327: 1–23.
- 37 Yan J, Jie Z, Hou L et al. Parenchymal expression of CD40 exacerbates adenovirus-induced hepatitis in mice. Hepatology 2011; 53: 1455–1467.
- 38 Adams DH, Harvath L, Bottaro DP et al. Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 7144–7148.
- 39 Ohnishi H, Oka K, Mizuno S, Nakamura T. Identification of mannose receptor as receptor for hepatocyte growth factor beta-chain: novel ligand-receptor pathway for enhancing macrophage phagocytosis. J. Biol. Chem. 2012; 287: 13371–13381.
- 40 Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J. Am. Soc. Nephrol. 2004; 15: 2637–2647.
- 41 Gong R, Rifai A, Ge Y, Chen S, Dworkin LD. Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J. Biol. Chem. 2008; 283: 7401–7410.
- 42 Tinoco R, Alcalde V, Yang Y, Sauer K, Zuniga EI. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 2009; 31: 145–157.
- 43 Boettler T, Cheng Y, Ehrhardt K, von Herrath M. TGF-beta blockade does not improve control of an established persistent viral infection. Viral Immunol. 2012; 25: 232–238.
- 44 Garidou L, Heydari S, Gossa S, McGavern DB. Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection. J. Virol. 2012; 86: 7060–7071.
- 45 Jin HT, Anderson AC, Tan WG et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 2010; 107: 14733–14738.
- 46 McMahan RH, Golden-Mason L, Nishimura MI et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 2010; 120: 4546–4557.
- 47 Sabatos CA, Chakravarti S, Cha E et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 2003; 4: 1102–1110.
- 48 Sanchez-Fueyo A, Tian J, Picarella D et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 2003; 4: 1093–1101.
- 49 Teijaro JR, Ng C, Lee AM et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013; 340: 207–211.
- 50 Wilson EB, Yamada DH, Elsaesser H et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013; 340: 202–207.
Citing Literature
